Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Dermata Therapeutics reports findings from phase I trial of DMT-210 in acne rosacea

Sep. 30, 2016

CD1a is a potential new therapeutic target in inflammatory skin disease

Sep. 30, 2016

Patients with atopic dermatitis dosed in phase I trial of MOR-106

Sep. 30, 2016

Marketing approval for Galderma's Epiduo given by several European regulatory bodies

Sep. 29, 2016

Shire terminates collaboration agreement with Momenta Pharmaceuticals for M-923

Sep. 28, 2016

Lumicef set for first global launch in Japan this month

Sep. 28, 2016

Pilot study finds significant hair regrowth with ruxolitinib in alopecia areata

Sep. 28, 2016

FDA accepts for priority review dupilumab BLA for atopic dermatitis

Sep. 26, 2016

Genfit validates RORgammat inverse agonist drug candidates for pre-IND studies

Sep. 23, 2016

Kadmon initiates phase II trials of KD-025 in psoriasis and GvHD

Sep. 22, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...